Breaking News News Oligomerix Completes Ph 1a Clinical Study on OLX-07010 May 19, 2026 By vera This article is sourced from an external publication. Read the original → ← PreviousNanoDetection Technology™ and Oligomerix™ Announce Exclusive Global Licensing Agreement for Breakthrough | Neurodegenerative Diagnostic AntibodiesNext →Oligomerix Awarded $0.5 M phase I NIH SBIR Fast-Track Grant to Conduct Safety Studies that will Support Clinical Studies of OLX-07010 for Alzheimer’s Patients
